ATEC Alphatec Holdings, Inc.

QT35

Latest market price

7.04

-4.33-38.08%

Overview Short InterestFilings

ATECQT35Alphatec Holdings, Inc.·NASDAQ

Overview Short InterestFilings

7.04-38.08%

News

Down 38.1% — Alphatec Plunges 32%. A Bone-Graft Slump Hits the Spine Specialist's Stock. (barrons.com).

Medium confidence

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PRCT-5.42%$19.20 AORT-3.67%$22.58 ENOV-12.71%$19.91 CBLL-4.46%$26.58 IART-0.62%$12.75 IRMD-10.57%$76.68 SIBN-5.27%$21.23 BVS-10.36%$13.33

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.56	Insider Own	—	Shs Outstand	154.45M	Perf Week	-36.63%

Market Cap	1.09B	Forward P/E	11.55	EPS next Y	0.61	Insider Trans	0.30%	Shs Float	120.78M	Perf Month	-28.89%

Enterprise Value	1.60B	PEG	—	EPS next Q	—			Short Float	11.00%	Perf Quarter	-30.64%

Income	-87.00M	P/S	1.29	EPS this Y	—			Short Ratio	6.07	Perf Half Y	-32.50%

Sales	840.00M	P/B	51.76	EPS next Y	86.61%	ROA	-10.91%	Short Interest	13.28M	Perf YTD	-66.54%

Book/sh	0.14	P/C	13.59	EPS next 5Y	48.53%	ROE	-547.17%	52W High	23.29 -69.77%	Perf Year	-57.31%

Cash/sh	0.52	P/FCF	181.22	EPS past 3/5Y	—	ROIC	-4.09%	52W Low	6.81 3.38%	Perf 3Y	-30.30%

Dividend Est.	—	EV/EBITDA	49.95	Sales past 3/5Y	29.60% 39.43%	Gross Margin	66.70%	Volatility	6.34% 5.15%	Perf 5Y	-42.11%

Dividend TTM	—	EV/Sales	1.90	EPS Y/Y TTM	—	Oper. Margin	-3.11%	ATR (14)	0.81	Perf 10Y	17.73%

Dividend Ex-Date	—	Quick Ratio	1.22	Sales Y/Y TTM	15.23%	Profit Margin	-10.35%	RSI (14)	27.16	Recom	2.20

Dividend Gr. 3/5Y	—	Current Ratio	2.36	EPS Q/Q	—	SMA20	-33.79%	Beta	0.87	Target Price	16.22

Payout	0.00%	Debt/Eq	28.14	Sales Q/Q	12.18%	SMA50	-30.57%	Rel Volume	9.85	Prev Close	11.37

Employees	913	LT Debt/Eq	27.90	Earnings	Feb 23	SMA200	-33.32%	Avg Volume	2.77M	Price	7.04

IPO Date	Jun 01, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.38% -1.77%	Net Debt/EBITDA	15.97	Volume	27,292,279	Change	-38.08%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-05-26	Reiterated	UBS	Buy	$15 → $16
Aug-05-26	Reiterated	BMO Capital	Outperform	$11 → $12
Jul-28-26	Initiated	UBS	Buy	$15
Jul-23-26	Initiated	Stephens	Overweight	$15
Jul-08-26	Initiated	BMO Capital	Outperform	$11
Jul-08-26	Reiterated	Stifel Nicolaus		$20 → $13
May-06-26	Reiterated	Lake Street	Buy	$25 → $15
May-06-26	Reiterated	Canaccord Genuity	Buy	$25 → $23
May-06-26	Reiterated	Needham	Buy	$23 → $14
May-06-26	Reiterated	Piper Sandler	Overweight	$25 → $14

Latest News· Times ET

Oct-30-26

Oct-30-2604:48PM

Alphatec Holdings Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Alphatec Holdings (ATEC)prnewswire.com

01:15PM

ATEC Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Alphatec Holdings, Inc.globenewswire.com

08:53AM

Alphatec Plunges 32%. A Bone-Graft Slump Hits the Spine Specialist's Stock.barrons.com

Oct-29-26

Oct-29-2609:58PM

Alphatec Holdings, Inc. (ATEC) Q3 2026 Earnings Call Transcriptseekingalpha.com

08:15PM

Alphatec Q3 Earnings Call Highlightsmarketbeat.com

08:06PM

Alphatec (ATEC) Q3 Earnings and Revenues Lag Estimateszacks.com

04:05PM

ATEC Reports Third Quarter Financial Resultsbusinesswire.com

Oct-27-26

Oct-27-2610:01AM

Alphatec Holdings (ATEC) Offers Market Share Gains and Margin Expansion Potential, Madison Small Cap Fund SaysYahoo

Oct-19-26

Oct-19-2604:35PM

ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026businesswire.com

Oct-01-26

Oct-01-2604:46AM

Reviewing LogicMark (OTCMKTS:LGMKD) & Alphatec (NASDAQ:ATEC)defenseworld.net

Sep-30-26

Sep-30-2612:28PM

Alphatec CEO Miles Patrick Purchases 115,000 Shares for $1 Million. Is the Medical Tech Stock Now a Buy?fool.com

Sep-23-26

Sep-23-2604:35PM

ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategybusinesswire.com

Sep-14-26

Sep-14-2607:15AM

Alphatec (ATEC) Moves 19.7% Higher: Will This Strength Last?zacks.com

Sep-11-26

Sep-11-2606:43AM

Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On FridayBenzinga

Aug-21-26

Aug-21-2602:29AM

Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Recommendation of “Moderate Buy” from Brokeragesdefenseworld.net

Company

Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/30/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	840	764	612	482	—	—	—	—	—
Cost of Goods Sold Incl. D&A	280	232	187	172	—	—	—	—	—
Gross Profit	559	532	424	310	—	—	—	—	—
Selling, General and Administrative Excl. Other	517	499	450	374	—	—	—	—	—
Research and Development	77	76	81	70	—	—	—	—	—
Other Operating Expense	-8	39	29	40	—	—	—	—	—
Operating Income	-26	-82	-136	-173	—	—	—	—	—
Interest Expense	39	21	25	17	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-24	-40	-1	3	—	—	—	—	—
Net Income Before Taxes	-89	-143	-162	-187	—	—	—	—	—
Income Taxes	-2	0	0	0	—	—	—	—	—
Consolidated Net Income	-87	-143	-162	-187	—	—	—	—	—
Net Income From Continuing Operations	-87	-143	-162	-187	—	—	—	—	—
Net Income	-87	-143	-162	-187	—	—	—	—	—
EPS (Recurring)	-0.56	-0.96	-1.13	-1.54	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.56	-0.96	-1.13	-1.54	—	—	—	—	—
EPS (Diluted)	-0.56	-0.96	-1.13	-1.54	—	—	—	—	—
EBITDA	32	-40	-54	-111	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	1.32	4.13	2.15	3.79	—	—	—	—	—
Gross Margin	66.55	69.63	69.28	64.32	—	—	—	—	—
Operating Margin	-3.10	-10.73	-22.22	-35.89	—	—	—	—	—
Net Margin	-10.36	-18.72	-26.47	-38.80	—	—	—	—	—
Shares Outstanding	157	150	143	121	—	—	—	—	—
Market Capitalization	1,105	3,156	1,313	1,828	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Miles Patrick	CEO	Sep 10 '26	Buy	8.81	115,000	1,013,150	5,893,551	Sep 10
Marshall Tyson Eliot	GENERAL COUNSEL & CORP. SEC.	Aug 05 '26	Sale	9.65	8,168	78,821	630,398	Aug 07
MCGINNIS KAREN K	Director	Jun 11 '26	Sale	8.01	6,050	48,461	94,671	Jun 12
Valentine Keith	Director	May 11 '26	Buy	7.00	35,000	245,000	232,271	May 11
Valentine Keith	Director	May 08 '26	Buy	7.54	43,847	330,606	197,271	May 11
Valentine Keith	Director	May 07 '26	Buy	7.49	56,153	420,586	153,424	May 11
Marshall Tyson Eliot	GENERAL COUNSEL & CORP. SEC.	Apr 07 '26	Option Exercise	2.52	102,500	258,050	661,959	Apr 09
Koning John Todd	CHIEF FINANCIAL OFFICER	Mar 13 '26	Sale	12.36	79,789	986,192	600,721	Mar 17
Lish Scott	CHIEF OPERATING OFFICER	Mar 13 '26	Sale	12.30	260,535	3,204,581	815,704	Mar 17
Sponsel David	EVP, SALES	Mar 11 '26	Sale	12.52	163,452	2,046,419	504,932	Mar 13
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Mar 09 '26	Sale	12.45	82,765	1,030,424	1,726,209	Mar 10
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Mar 06 '26	Sale	12.22	33,602	410,616	1,808,974	Mar 10
Marshall Tyson Eliot	GENERAL COUNSEL & CORP. SEC.	Mar 05 '26	Sale	12.49	88,835	1,109,549	559,459	Mar 09
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Feb 12 '26	Option Exercise	2.14	251,176	538,501	1,424,201	Feb 17
Sponsel David	EVP, SALES	Feb 05 '26	Sale	13.79	60,425	833,261	349,500	Feb 06

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.